i-SENS reported on the 11th that its consolidated recruitment profit for the previous year was 2.1 billion won, down 80.8% from the previous year. Sales during the same period increased by 9.6% year-on-year to 290.6 billion won.
By institutional sector, the blood glucose business section grew by 7.6% compared to the same period last year, while the point-of-care testing (POCT) sector saw an 18.1% increase. The continuous glucose monitoring (CGM) sector achieved a result of 6 billion won.
An i-SENS official noted, "The poor performance of our U.S. subsidiary AgaMatrix placed significant burden on last year's results," adding that "improvements in management performance are expected this year due to the restructuring carried out last year."
i-SENS's flagship product is the domestic first CGM "CareSense Air," which was launched in September 2023. It was also released in the European market in February last year.
The company plans to launch an upgraded product of CareSense Air in the domestic market in April. In the UK, insurance registration will be completed this month. As a result, the number of countries where CareSense Air is covered by insurance has increased to three: Hungary, Estonia, and the UK. Notably, CareSense Air has recorded high sales in Hungary. In addition to the advanced version of CareSense Air, an improved performance version, "CareSense Air2," is also in preparation.